Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.

Saved in:
Bibliographic Details
Title: Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.
Authors: Stringer-Reasor EM; Department of Medicine, Section of Hematology/Oncology, University of Alabama at Birmingham, 1720 2nd Avenue South, NP 2510, Birmingham, AL, 35294-3300, USA. esreasor@uabmc.edu., Saha P; Department of Medicine, Endeavor Health, Evanston, IL, USA., Kocherginsky M; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine Chicago, Chicago, IL, USA., Lastra R; Department of Pathology, The University of Chicago, Chicago, IL, USA., Baker G; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Lenygel E; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA., Karrison T; Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA., Olalde L; Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA., Mokrzycki E; Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA., Hahn OM; Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA., Hoffman PC; Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA., Conzen SD; Department of Medicine, Section of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Fleming GF; Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA., Nanda R; Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Oct; Vol. 213 (3), pp. 347-354. Date of Electronic Publication: 2025 Aug 08.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1573-7217
DOI:10.1007/s10549-025-07783-7